Literature DB >> 29531894

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs).

Santiago Viteri1, Rafael Rosell2.   

Abstract

Entities:  

Year:  2018        PMID： 29531894      PMCID： PMC5835633          DOI： 10.21037/tlcr.2017.12.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

Review 1.  Physiological and pathological roles for microRNAs in the immune system.

Authors:  Ryan M O'Connell; Dinesh S Rao; Aadel A Chaudhuri; David Baltimore
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

Review 2.  Overcoming cellular barriers for RNA therapeutics.

Authors:  Steven F Dowdy
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 3.  Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy.

Authors:  Jennifer A MacDiarmid; Himanshu Brahmbhatt
Journal:  Curr Opin Biotechnol       Date:  2011-05-06       Impact factor: 9.740

4.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

5.  Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.

Authors:  Shingo Kanemura; Kozo Kuribayashi; Norihiko Funaguchi; Eisuke Shibata; Koji Mikami; Hiroshi Doi; Kazuhiro Kitajima; Seiki Hasegawa; Takashi Nakano
Journal:  Eur J Radiol       Date:  2016-11-05       Impact factor: 3.528

6.  Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Authors:  G Reid; M E Pel; M B Kirschner; Y Y Cheng; N Mugridge; J Weiss; M Williams; C Wright; J J B Edelman; M P Vallely; B C McCaughan; S Klebe; H Brahmbhatt; J A MacDiarmid; N van Zandwijk
Journal:  Ann Oncol       Date:  2013-10-22       Impact factor: 32.976

7.  Ligand-targeted bacterial minicells: Futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells.

Authors:  Mehul Jivrajani; Manish Nivsarkar
Journal:  Nanomedicine       Date:  2016-07-02       Impact factor: 5.307

Review 8.  New Concepts in the Treatment of Malignant Pleural Mesothelioma.

Authors:  Ori Wald; David J Sugarbaker
Journal:  Annu Rev Med       Date:  2017-10-13       Impact factor: 13.739

Review 9.  Malignant mesothelioma: global incidence and relationship with asbestos.

Authors:  Claudio Bianchi; Tommaso Bianchi
Journal:  Ind Health       Date:  2007-06       Impact factor: 2.179

10.  Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Authors:  Andrea B Apolo; Jeffrey R Infante; Ani Balmanoukian; Manish R Patel; Ding Wang; Karen Kelly; Anthony E Mega; Carolyn D Britten; Alain Ravaud; Alain C Mita; Howard Safran; Thomas E Stinchcombe; Marko Srdanov; Arnold B Gelb; Michael Schlichting; Kevin Chin; James L Gulley
Journal:  J Clin Oncol       Date:  2017-04-04       Impact factor: 44.544
View more
  9 in total

Review 1.  MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

2.  Loss of miR-16 contributes to tumor progression by activation of tousled-like kinase 1 in oral squamous cell carcinoma.

Authors:  Shousen Hu; Honghan Wang; Dan Yan; Wuhao Lu; Pei Gao; Weihua Lou; Xiangzhen Kong
Journal:  Cell Cycle       Date:  2018-10-09       Impact factor: 4.534

3.  Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin.

Authors:  Esteban A Orellana; Ahmed M Abdelaal; Loganathan Rangasamy; Srinivasarao Tenneti; Sunghyun Myoung; Philip S Low; Andrea L Kasinski
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-11       Impact factor: 8.886

4.  Answer to Controversy: miR-10a Replacement Approaches Do Not Offer Protection against Chemotherapy-Induced Gonadotoxicity in Mouse Model.

Authors:  Chrysanthi Alexandri; Christina-Anna Stratopoulou; Isabelle Demeestere
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

Review 5.  Recent applications and strategies in nanotechnology for lung diseases.

Authors:  Wenhao Zhong; Xinyu Zhang; Yunxin Zeng; Dongjun Lin; Jun Wu
Journal:  Nano Res       Date:  2021-01-08       Impact factor: 8.897

Review 6.  The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.

Authors:  Fatimat Kipkeeva; Tatyana Muzaffarova; Alexandra Korotaeva; Danzan Mansorunov; Pavel Apanovich; Maxim Nikulin; Olga Malikhova; Ivan Stilidi; Alexander Karpukhin
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

7.  miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.

Authors:  Rihan El Bezawy; Stefano Percio; Chiara Maura Ciniselli; Michelandrea De Cesare; Gennaro Colella; Matteo Dugo; Silvia Veneroni; Valentina Doldi; Silvia Martini; Dario Baratti; Shigeki Kusamura; Paolo Verderio; Marcello Deraco; Paolo Gandellini; Nadia Zaffaroni; Valentina Zuco
Journal:  Cancer Gene Ther       Date:  2022-03-29       Impact factor: 5.854

Review 8.  miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.

Authors:  Maria Teresa Di Martino; Caterina Riillo; Francesca Scionti; Katia Grillone; Nicoletta Polerà; Daniele Caracciolo; Mariamena Arbitrio; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

Review 9.  MicroRNA as a Potential Therapeutic Molecule in Cancer.

Authors:  Joanna Szczepanek; Monika Skorupa; Andrzej Tretyn
Journal:  Cells       Date:  2022-03-16       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.